Vanguard Group
CGON icon

Vanguard Group’s CG Oncology CGON Stock Holding History

Vanguard Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$272M Sell
6,539,482
-37,799
-0.6% -$1.56M ﹤0.01% 1381
2025
Q3 		$265M Buy
6,577,281
+670,770
+11% +$19.5M ﹤0.01% 1396
2025
Q2 		$154M Buy
5,906,511
+70,191
+1% +$1.69M ﹤0.01% 1639
2025
Q1 		$143M Sell
5,836,320
-24,762
-0.4% -$697K ﹤0.01% 1634
2024
Q4 		$168M Buy
5,861,082
+779,730
+15% +$26.7M ﹤0.01% 1621
2024
Q3 		$192M Buy
5,081,352
+2,837,231
+126% +$99.5M ﹤0.01% 1562
2024
Q2 		$70.8M Buy
2,244,121
+19,103
+0.9% +$662K ﹤0.01% 2006
2024
Q1 		$97.7M Buy
+2,225,018
New +$90.9M ﹤0.01% 1884

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's CGON Position: Q4 2025 in Review

Vanguard Group reduced its CG Oncology (CGON) stake by 0.57% in Q4 2025, selling an estimated $1.56M and leaving 6,539,482 shares worth $272M. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

Vanguard Group first reported a position in CGON in Q1 2024 and has held it in 8 quarters since. 195 funds tracked by Wall St. Rank hold CGON as of Q4 2025.

  • Vanguard Group held 6,539,482 shares of CG Oncology worth $272M as of Q4 2025.
  • Vanguard Group sold 37,799 CG Oncology shares in Q4 2025, an estimated $1.56M.
  • CG Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1381 holding.
  • Vanguard Group first reported a position in CG Oncology in Q1 2024 and has held it in 8 quarters since.
  • 195 funds tracked by Wall St. Rank held CG Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.